Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

CD22-targeted immunoconjugate characterized at EORTC-NCI-AACR meeting

Nov. 27, 2002

A novel prostate cancer vaccine reported to induce specific immune responses

Nov. 27, 2002

New data on the immunomodulatory effects of IL-2 + histamine in advanced melanoma

Nov. 27, 2002

MLN-2704 enters phase I in androgen-independent prostate cancer

Nov. 26, 2002

Ivax to develop LMB-9

Nov. 25, 2002

IGN-311 reported safe in rhesus monkeys

Nov. 22, 2002

CC-5013 effective and well tolerated in multiple myeloma

Nov. 22, 2002

Enrollment completed for BLP25 liposomal vaccine study in non-small cell lung cancer

Nov. 19, 2002

Albuleukin superior to rIL-2 in mouse model of metastatic melanoma

Nov. 18, 2002

Potential use of vaccines in advanced prostate cancer

Nov. 15, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...